Bristol-Myers Squibb Co.'s Orencia reduced flare-ups in children with rheumatoid arthritis by a third compared with those who took placebo, an Italian study found. Researchers said the drug can help pediatric patients who do not respond to an older medication, methotrexate, or tumor necrosis factor blockers, which include Johnson & Johnson's Remicade and Abbott Laboratories' Humira.

Full Story:

Related Summaries